ALGS (STOCKS)
Aligos Therapeutics, Inc. Common Stock
$5.110000
-0.170000 (-3.22%)
Prev close: $5.280000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Lawrence M. Blatt
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $31.75M
- Employees
- 70
- P/E (TTM)
- -0.61
- P/B (TTM)
- 1.03
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-2.21 | $-2.27 | +0.0575 | +2.54% |
|
Dec 2025 (Q4)
|
$-1.91 | $-1.89 | -0.0210 | -1.11% |
|
Sep 2025 (Q3)
|
$-3.04 | $-1.94 | -1.1020 | -56.86% |
|
Jun 2025 (Q2)
|
$-1.53 | $-2.41 | +0.8806 | +36.53% |
Financial Statements
| Revenues | $4.71M |
| Benefits Costs and Expenses | $94.44M |
| Costs And Expenses | $94.44M |
| Operating Expenses | $100.38M |
| Research and Development | $78.30M |
| Other Operating Expenses | $22.07M |
| Operating Income/Loss | -$95.67M |
| Income/Loss From Continuing Operations After Tax | -$90.32M |
| Income/Loss From Continuing Operations Before Tax | -$89.73M |
| Income Tax Expense/Benefit | $588.00K |
| Interest Income/Expense After Provision For Losses | $1.50M |
| Interest Income/Expense Operating, Net | $1.50M |
| Net Income/Loss | -$90.32M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$90.32M |
| Net Income/Loss Available To Common Stockholders, Basic | -$90.32M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$8.79 |
| Diluted Earnings Per Share | -$8.79 |
| Basic Average Shares | 31,291,682 |
| Diluted Average Shares | 31,291,682 |
| Assets | $64.56M |
| Current Assets | $59.63M |
| Cash | $54.90M |
| Other Current Assets | $4.73M |
| Noncurrent Assets | $4.93M |
| Fixed Assets | $1.59M |
| Other Non-current Assets | $3.34M |
| Liabilities | $32.77M |
| Current Liabilities | $23.32M |
| Accounts Payable | $7.64M |
| Wages | $4.22M |
| Other Current Liabilities | $11.46M |
| Noncurrent Liabilities | $9.45M |
| Equity | $31.79M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $31.79M |
| Liabilities And Equity | $64.56M |
| Net Cash Flow From Operating Activities | -$84.72M |
| Net Cash Flow From Operating Activities, Continuing | -$84.72M |
| Net Cash Flow From Investing Activities | $41.17M |
| Net Cash Flow From Investing Activities, Continuing | $41.17M |
| Net Cash Flow From Financing Activities | -$169.00K |
| Net Cash Flow From Financing Activities, Continuing | -$169.00K |
| Net Cash Flow | -$43.72M |
| Net Cash Flow, Continuing | -$43.72M |
| Comprehensive Income/Loss | -$90.30M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$90.33M |
| Other Comprehensive Income/Loss | -$74.44M |
| Other Comprehensive Income/Loss Attributable To Parent | -$9.00K |